attention deficit hyperactivity disorder/癲癇性発作

Throughout this application, various references are cited, using arabic numbers within parentheses. Full citations for these references can be found at the end of the specification, immediately preceding the claims. These publications, in their entireties, are hereby incorporated by reference into

This invention relates to uses of compounds. In particular, it relates to the use of compounds in the treatment or prevention of diseases and biomedical conditions such as, seizure-related disorders, bipolar disorders, mania, depression, migraine, attention deficit hyperactivity disorders, latent

PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1834/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050909 filed on 3 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this

PRIORITY This application is a national phase filing of the Patent Cooperation Treaty (PCT) application # PCT/IB2013/050740 titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY" filed on Jan. 29, 2013. Published with WIPO Publication # WO/2013/167986 which further claims priority to patent

PRIORITY This application is a national phase filing of the Patent Cooperation Treaty (PCT) application #PCT/IB2013/050711 titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS" filed on Jan. 28, 2013 Published with WIPO Publication #WO/2013/167985, which further claims

CROSS REFERENCE TO RELATED APPLICATIONS This is a National Stage of International Application No. PCT/JP2009/067441 filed Sep. 30, 2009, claiming priority based on Japanese Patent Application No. 2008-257072 filed Oct. 2, 2008, the contents of all of which are incorporated herein by reference in

FIELD OF THE INVENTION The present invention generally relates to deuterium-enriched N-acetylamino-(piperazinyl)-butyl)-alkylsulfonamides of formula 1, their pharmaceutically acceptable salts, synthesis and methods of use thereof. These compounds are 5-HT (serotonin) receptor modulators more

CROSS REFERENCE TO RELATED APPLICATION This application claims the priority of Korean Patent Application No. 10-2007-0022845, filed on Mar. 8, 2007 in the KIPO (Korean Intellectual Property Office), the disclosure of which are incorporated herein in their entirety by reference. Further, this

TECHNICAL FIELD The present invention relates to a piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable salt comprising the same. BACKGROUND ART Dopamine is a neurotransmitter essential for neuronal signal transduction in animal brains including

BACKGROUND OF THE INVENTION Serotonin (5-hydroxy-tryptamine) (5-HT) receptors play an important role in many physiological and pathological functions like anxiety, sleep regulation, aggression, feeding and depression. The 5-HT receptors are distributed throughout the body and can be divided is into

TECHNICAL FIELD The present invention is in the field of chemical synthesis of stereoisomers and more particularly the exo-S-mecamylamine stereoisomer and the use of exo-S-mecamylamine in medical treatments. BACKGROUND ART Mecamylamine (N,2,3,3-tetramethylbicyclo-[2.1.1]heptan-2-amine hydrochloride,

BACKGROUND (1) Field of the Invention The present invention is in the field of chemical synthesis of stereoisomers and more particularly the exo-S-mecamylamine stereoisomer and the use of exo-S-mecamylamine in medical treatments. (2) Description of Related Art Mecamylamine

BACKGROUND (1) Field of the Invention The present invention is in the field of chemical synthesis of stereoisomers and more particularly the exo-S-mecamylamine stereoisomer and the use of exo-S-mecamylamine in medical treatments. (2) Description of Related Art Mecamylamine

BACKGROUND (1) Field of the Invention The present invention is in the field of chemical synthesis of stereoisomers and more particularly the exo-S-mecamylamine stereoisomer and the use of exo-S-mecamylamine in medical treatments. (2) Description of Related Art Mecamylamine

BACKGROUND (1) Field of the Invention The present invention is in the field of chemical synthesis of stereoisomers and more particularly the exo-S-mecamylamine stereoisomer and the use of exo-S-mecamylamine in medical treatments. (2) Description of Related Art Mecamylamine